A new paper published in Psychedelic Medicine introduces a novel model combining Meaning-Centered Psychotherapy (MCP) with psilocybin-assisted therapy (PAT) for patients with advanced cancer and depression. Developed from Sunstone Therapies’ investigator-initiated trial, the approach—called MCP-PSIL—aims to help patients reduce distress and find deeper meaning while navigating serious illness.
In psychedelic therapy clinical research, setting clear expectations is paramount. Transparent communication about potential disappointments can significantly reduce anxiety and foster a more grounded, trusting, and ultimately, healing journey for participants.
Co-founder and CEO, Dr. Manish Agrawal, recently shared his expertise and vision for the future of psychedelic-assisted therapy in oncology in a four-part interview series with Pharmacy Times’ Lead Editor, Alana Hippensteele.
Sunstone is pleased to begin enrollment of two clinical studies exploring the therapeutic potential of DMT (N,N-dimethyltryptamine) and its analogs.
Manish Agrawal, MD, Co-Founder and CEO of Sunstone Therapies Manish Agrawal, MD, brings an extensive academic, clinical, and research background […]
Psychedelic therapy can helps patients face difficult emotions with curiosity, supporting deep healing and lasting change.
Sunstone Therapies Co-Founders Dr. Manish Agrawal and Kim Roddy spoke with Psychedelic Alpha’s Editor, Josh Hardman, about the challenges and insights they’ve gained after delivering hundred of psychedelic therapy sessions.
Psychedelic Medicine–History and Clinical Research January 30, 2025 Psychedelic Medicine: History and Clinical Research explores the resurgence of psychedelics in […]
Manish Agrawal, MD joins Living Medicine host, Dr. Sandra Newes to discuss the challenges and future of psychedelic-assisted therapy research.